Odylia’s Annual Rare Disease Awareness Event – 2026, Washington DC
Odylia is pioneering new approaches to drug development and tackling the barriers that prevent the rare disease community from accessing meaningful therapeutic opportunities. By building a collaborative network of individuals, organizations, and innovators who recognize the urgency of this challenge, Odylia is driving forward solutions that do not currently exist.
Each year, Odylia hosts a gathering designed to unite people, companies, and institutions committed to reimagining how treatments for rare diseases are developed. This event creates a space for the rare disease community to learn from one another, share experiences, and form new partnerships with changemakers, both those deeply rooted in the field and those newly entering it. Through these conversations, the event elevates awareness and opens doors to fresh perspectives and alternative pathways that can accelerate progress for rare disease treatments.
We are energized by the opportunity to spark dialogue, inspire collaboration, and highlight what is possible when we work together to change the trajectory of rare disease drug development. This year’s event will be held in Washington DC on February 25th. Please reach out, info@odylia.org, if you would like to attend and we can send you more information about the event.
2026 Rare Disease Event Sponsors
Andelyn Biosciences
Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization, and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn’s deep scientific expertise has resulted in the production of cGMP material for more than 450 clinical batches and 75 global clinical trials. Operating out of its development and manufacturing facilities in Columbus, Ohio, Andelyn supports its clients in developing cell and gene therapies from concept through plasmid engineering and manufacturing, process and analytical development, and cGMP clinical and commercial manufacturing. Andelyn can accelerate programs and deliver high-quality products by developing and manufacturing processes on its configurable, data-driven AAV Curator® Platform or tech transfer in an established client program. Capabilities include cGMP manufacturing for suspension processes up to a 2,000-liter and adherent processes. A rigorous quality system, regulatory support, and supply chain vertical integration further advantages clients in bringing their critical therapies to market. For more information, please visit andelynbio.com.
Upstream Genes
Upstream Genes is a nonprofit whose mission is to cure forms of Retinitis Pigmentosa (RP) and other inherited diseases linked to mutations in the HGSNAT gene. We want to fund the next wave of breakthroughs in retinal gene therapies.
Dash Bio
Dash Bio is the only tech-first bioanalysis CRO that delivers GLP-compliant results in days, not months. Our fully automated platforms scale to any study size, all with fixed, transparent pricing. That speed and flexibility makes Dash ideal for rare disease programs where every day counts and budgets are tight.
As an independent nonprofit organization, Odylia is proud to have earned the GuideStar Platinum Seal of Transparency and Charity Navigator 4 star rating, indicating that we share quantitative metrics on the progress we are making toward our mission and the highest levels of transparency in our operations.
